SCHEMBL25568933

SCHEMBL25568933

Cc1ccc(CN2CCC(NC(=O)COc3ccc(C(=O)c4ccc(Cl)cc4)cc3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADIPOR2 Q86V24 1/20 0.73
ADIPOR1 Q96A54 1/20 0.73
USP2 O75604 1/20 0.63
ATF4 P18848 3/20 0.62
POLB P06746 1/20 0.62
CCR2 P41597 1/20 0.58
MCHR1 Q99705 4/20 0.57
SIGMAR1 Q99720 1/20 0.54
LMNA P02545 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPK1 P28482 1/20 0.53
DRD4 P21917 2/20 0.53
FAAH O00519 1/20 0.53
BCHE P06276 1/20 0.53
ACHE P22303 1/20 0.53
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24514196 0.92 ADIPOR2 (0.73) ADIPOR2ADIPOR1USP2ATF4POLB
SCHEMBL17946118 0.91 ADIPOR2 (0.88) ADIPOR2ADIPOR1USP2ATF4POLB
SCHEMBL17950883 0.90 ADIPOR2 (0.90) ADIPOR2ADIPOR1USP2ATF4POLB
SCHEMBL25568934 0.90 ADIPOR2 (0.67) ADIPOR2ADIPOR1USP2ATF4POLB
SCHEMBL24514569 0.88 ADIPOR2 (0.70) ADIPOR2ADIPOR1USP2ATF4POLB
SCHEMBL17656861 0.85 ATF4 (0.86) ATF4LMNASMN1; SMN2MAPK1KMT2A
SCHEMBL17658492 0.85 ATF4 (0.86) ATF4LMNASMN1; SMN2MAPK1KMT2A
SCHEMBL17950896 0.85 POLB (0.63) ADIPOR2ADIPOR1USP2POLBMCHR1
SCHEMBL17938602 0.84 ADIPOR2 (1.00) ADIPOR2ADIPOR1USP2POLBMCHR1
SCHEMBL17658584 0.84 ATF4 (0.76) ATF4POLBLMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234923-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES TRUSTEES OF TUFTS COLLEGE 2023-07-27 US disclosed
US-11655212-B2 Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes TRUSTEES OF TUFTS COLLEGE (US) 2023-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655212-B2 Using adiponectin receptor agonists to treat inflammation and bone diseases in diabetes ADIPOR1, ADIPOR2, GPR119 ADIPOR2 2/4885ADIPOR1 1/4885USP2 3113/4885
US-20230234923-A1 USING ADIPONECTIN RECEPTOR AGONISTS TO TREAT INFLAMMATION AND BONE DISEASES IN DIABETES ADIPOR1, ADIPOR2, GPR119 ADIPOR2 2/4885ADIPOR1 1/4885USP2 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.